Back HCV Populations

HCV Populations

Coverage of 4th International Symposium on Hepatitis Care in Substance Users (INHSU 2015)

Hepatitis C treatment for people who inject drugs, including those receiving opioid substitution therapy (OST), was a major theme of the 4th International Symposium on Hepatitis Care in Substance Users (INHSU 2015), October 7-9 in Sydney. 

INHSU 2015 Highlights Hepatitis C Prevention and Treatment for People Who Inject Drugs

INHSU 2015: HCV Treatment Works Well for People Who Inject Drugs, but Barriers to Access Remain

INHSU website

10/16/15

alt

INHSU 2015: HCV Treatment Works Well for People Who Inject Drugs, but Barriers to Access Remain

Hepatitis C treatment for people who inject drugs, including those receiving opioid substitution therapy (OST), was a major theme of the 4th International Symposium on Hepatitis Care in Substance Users (INHSU 2015) last week in Sydney. Studies show that treatment using new interferon-free regimens can be highly effective for this population, but barriers including high drug costs and stigma against drug users have hindered widespread access to therapy.

alt

Read more:

People Who Inject Drugs Should Have Access to Hepatitis C Treatment, Expert Panel Recommends

New recommendations on hepatitis C treatment and care encourage physicians to offer treatment to all people who inject drugs who are diagnosed with HCV infection, and to offer a comprehensive package of social support and harm reduction to enable people to adhere to treatment. The recommendations are published this month in the International Journal of Drug Policy, coinciding with the 4th International Symposium on Hepatitis Care in Substance Users taking place this week Sydney, which focuses on the management of hepatitis among drug users.

alt

Read more:

INHSU 2015 Highlights Hepatitis C Prevention and Treatment for People Who Inject Drugs

An international group of researchers, healthcare providers, advocates, people who use drugs, and people living with hepatitis C are gathering this week in Sydney for the 4th International Symposium on Hepatitis Care in Substance Users, focusing on hepatitis C prevention, care, and treatment for injection drug users. The full program, with links to many of the presentations, is available online. Follow conference news on Twitter #INHSU2015.

alt

Read more:

People on Opiate Substitution Therapy Respond Well to AbbVie Hepatitis C Treatment

Nearly all genotype 1 hepatitis C patients with a history of injection drug use who were on stable opiate substitution therapy with methadone or buprenorphine were cured using AbbVie's Viekira Pak regimen plus ribavirin for 12 weeks, according to a Phase 2 study described in the August 2015Journal of Hepatology. No interactions were seen between opiate substitution therapy and the hepatitis C drugs.

alt

Read more: